MannKind Corporation

MannKind Corporation

MNKDNYSE / NASDAQHealthcareSmall cap

$3.85-$0.10 (-2.5%)

Last close · Data as of Nov 20, 2026

Market cap
$1.1B
P/E
185.5x
EV / EBITDA
26.8x
Revenue
$349.0M
Net margin
1.7%
ROCE
7.5%

-22.5% over the last year

MannKind Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+24.2%
3M
-9.6%
6M
+18.5%
1Y
-22.5%
5Y
-18.9%

52-week range

Day change -$0.10 (-2.5%) from $3.95 to $3.85 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MNKD, bought on each weekday since 2021.

News & filings

What MannKind filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Revenue grew 51.8% a year over three years.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

Read moreShow less

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Sector
Healthcare
Shares outstanding
293.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.1B
P/E
185.5x
P/B
-21.3x
EV / EBITDA
26.8x
EV / Sales
4.0x
P/S
3.1x
52-week high
$6.21
52-week low
$2.28

Profitability

Operating margin
13.3%
Net margin
1.7%
EBITDA margin
14.8%
ROE
-11.5%
ROCE
7.5%
ROIC
16.2%
ROA
0.7%
Asset turnover
0.44

Growth

Revenue
$349.0M
Revenue growth, 1Y
22.2%
Revenue CAGR, 3Y
51.8%
Net profit growth, 1Y
-78.7%
Free cash flow
$13.7M

Solvency

Current ratio
1.70
Debt / Equity
-7.20
Debt / Assets
0.46
CFO / Net profit
3.11
Cash / Market cap
6.9%

Where the revenue went

Of every $100 of FY2025 revenue, $2 was left as net income.

MannKind Corporation income statement flow, FY2025
MannKind Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$88.0M
RevenueGross profit$261.0M
Gross profitResearch and development$66.3M
Gross profitSelling, general and administrative$144.1M
Gross profitOther operating expenses$4.0M
Gross profitOperating income$46.5M
Operating incomePretax income$1.4M
Operating incomeInterest and other expense$45.1M
Pretax incomeNet income$1.4M
Tax benefit and otherNet income$4.5M

Revenue and net profit

Revenue grew 22.2% in FY2025; net profit is the dashed line.

MannKind Corporation revenue and net profit by fiscal year
MannKind Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$99.8M-$87.4M
FY2023$199.0M-$11.9M
FY2024$285.5M$27.6M
FY2025$349.0M$5.9M

Cash flows

FY2025: $18.3M from operations, $13.7M free after investment (dashed).

MannKind Corporation operating and free cash flow by fiscal year
MannKind Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$80.7M-$88.3M
FY2023$34.1M-$8.3M
FY2024$42.5M$32.8M
FY2025$18.3M$13.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$349.0M+22.2%1Y
EBITDA
$51.5M-31.9%1Y
Net profit
$5.9M-78.7%1Y
Cash from operations
$18.3M-57.1%1Y
Free cash flow
$13.7M-58.3%1Y
Revenue CAGR, 3Y
51.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$349.0M$51.5M$5.9M$13.7M-11.5%+22.2%-78.7%

Monthly returns

Month-by-month returns of MNKD across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$792.2M
Liabilities$843.2M
Equity-$51.0M
Paid-in capital$3.1B
Retained earnings-$3.2B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; MNKD highlighted.

P/E against peers

MNKD trades at 185.5x earnings against a peer median of -7.0x.

  1. MannKind Corporation (this company)185.5x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Savara Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
MannKind CorporationMNKDthis company$1.1B185.5x-21.3x-11.5%26.8x
OPKO Health, Inc.OPK$1.1B-4.9x0.9x-17.8%-27.4x
Aktis Oncology, Inc.AKTS$1.1B-17.3x-7.5x43.6%-14.8x
Savara Inc.SVRA$1.1B-9.1x5.3x-58.5%-8.8x
Omada Health, Inc.OMDA$1.1B-84.7x4.7x-5.6%-181.0x
Xeris Biopharma Holdings, Inc.XERS$1.1B1916.5x77.6x4.0%28.6x
Collegium Pharmaceutical, Inc.COLL$1.1B16.9x3.5x20.8%4.1x
CONMED CorporationCNMD$1.1B22.5x1.0x4.6%10.5x
Azenta, Inc.AZTA$1.1B-18.9x0.6x-3.2%20.8x
Peer median—-7.0x2.3x0.4%-2.4x

Year-to-date ROI

MNKD since 1 January, against earlier years.

Historical volatility

MNKD's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

MannKind Corporation operating margin by fiscal year
MannKind Corporation operating margin by fiscal year
DateOperating margin
FY2022-69.1%
FY20235.3%
FY202424.1%
FY202513.3%
LineFY2025
Cost of revenueCost Of Revenue$88.0M
Gross profitGross Profit$261.0M
Operating expensesOperating Expense$214.5M
Research and developmentResearch And Development$66.3M
Other operating expensesOther Operating Expenses—
Depreciation and amortisationDepreciation And Amortization In Income Statement$4.0M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$4.0M
Amortization$4.0M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$4.0M
Total expensesTotal Expenses$302.4M
Pretax incomePretax Income$1.4M

Learn while you research

Academy chapters picked for MannKind Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 185.5, learn when high multiples are justified.6 min read
  3. 03 Growth Investing22% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →